Evidence map›Paper›PMID 39334347›Full record

Trial reportBMC medical informatics and decision making2024

Use of web-based decision support to improve informed choice for chemoprevention: a qualitative analysis of pre-implementation interviews (SWOG S1904).

Alissa M Michel, Haeseung Yi, Jacquelyn Amenta, Nicole Collins, Anna Vaynrub, Subiksha Umakanth, Garnet Anderson, Katie Arnold, Cynthia Law, Sandhya Pruthi and 29 more

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC medical informatics and decision making, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04496739 (Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice Among Women With Atypical Hyperplasia or Lobular Carcinoma In Situ - Making Informed Choices on Incorporating Chemoprevention Into Care), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04496739 naactive not recruitingnot on this map

Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice Among Women With Atypical Hyperplasia or Lobular Carcinoma In Situ - Making Informed Choices on Incorporating Chemoprevention Into Care (MiChoice)

TypeinterventionalSponsorSWOG Cancer Research NetworkRan2020 to 2028Enrolled412ConditionsAtypical Hyperplasia of the Breast, Lobular Breast Carcinoma In Situ, Pleomorphic Lobular Breast Carcinoma In SituArmsCancer Educational Materials, Decision Aid, Interview, Questionnaire Administration
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

39 authors.

Alissa M MichelColumbia University Irving Medical Center, 177 Fort Washington Ave, Suite 6-435, New York, NY, 10032, USA. Am5314@cumc.columbia.edu.
Haeseung YiColumbia University Irving Medical Center, 177 Fort Washington Ave, Suite 6-435, New York, NY, 10032, USA.
Jacquelyn AmentaColumbia University Irving Medical Center, 177 Fort Washington Ave, Suite 6-435, New York, NY, 10032, USA.
Nicole CollinsColumbia University Irving Medical Center, 177 Fort Washington Ave, Suite 6-435, New York, NY, 10032, USA.
Anna VaynrubColumbia University Irving Medical Center, 177 Fort Washington Ave, Suite 6-435, New York, NY, 10032, USA.
Subiksha UmakanthColumbia University Irving Medical Center, 177 Fort Washington Ave, Suite 6-435, New York, NY, 10032, USA.
Garnet AndersonSWOG Statistics and Data Management Center, Seattle, WA, USA.
Katie ArnoldSWOG Statistics and Data Management Center, Seattle, WA, USA.
Cynthia LawColumbia University Irving Medical Center, 177 Fort Washington Ave, Suite 6-435, New York, NY, 10032, USA.
Sandhya PruthiMayo Clinic, Rochester, MN, USA.
Ana Sandoval-LeonMiami Cancer Institute at Baptist Health South Florida, Miami, FL, USA.
Rachel ShirleyGood Samaritan Hospital Corvallis, Corvallis, OR, USA.
Maria Grosse PerdekampCarle Cancer Center, Urbana, IL, USA.
Sarah ColonnaHuntsman Cancer Institute / University of Utah Medical Center, Salt Lake City, UT, USA.
Stacy KrisherHoly Redeemer Hospital and Medical Center, Meadowbrook, PA, USA.
Tari KingDana-Farber Brigham Cancer Center, Brigham and Women's Hospital, Boston, MA, USA.
Lisa D YeeCity of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Tarah J BallingerIndiana University Simon Comprehensive Cancer Center, Indianapolis, IN, USA.
Christa Braun-InglisUniversity of Hawaii Cancer Center, Honolulu, HI, USA.
Debra A ManginoMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Kari WisinskiUniversity of Wisconsin Carbone Cancer Center, Madison, WI, USA.
Claudia A DeYoungKaiser Permanente NCORP, Vallejo, CA, USA.
Masey RossVirginia Commonwealth University, Richmond, VA, USA.
Justin FloydCancer Care Specialists of Illinois, Heartland NCORP, Decatur, IL, USA.
Andrea KasterSanford Roger Maris Cancer Center, Fargo, ND, USA.
Lindi VanderWaldeBaptist Memorial Health Care, Memphis, TN, USA.
Thomas J SaphnerAurora NCORP, Milwaukee, WI, USA.
Corrine ZarwanLahey Hospital & Medical Center, Burlington, MA, USA.
Shelly LoLoyola University Stritch School of Medicine, Maywood, IL, USA.
Cathy GrahamEmory University Hospital/Winship Cancer Institute, Atlanta, GA, USA.
Alison ConlinProvidence Cancer Institute, Portland, OR, USA.
Kathleen YostCancer Research Consortium of West Michigan NCORP, Kalamazoo, MI, USA.
Doreen AgneseThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Cheryl JerniganSWOG Cancer Research Network, San Antonio, TX, USA.
Dawn L HershmanColumbia University Irving Medical Center, 177 Fort Washington Ave, Suite 6-435, New York, NY, 10032, USA.
Marian L NeuhouserFred Hutchinson Cancer Center, Seattle, WA, USA.
Banu ArunThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Katherine D CrewColumbia University Irving Medical Center, 177 Fort Washington Ave, Suite 6-435, New York, NY, 10032, USA.
Rita KukafkaColumbia University Irving Medical Center, 177 Fort Washington Ave, Suite 6-435, New York, NY, 10032, USA.

Funding

The Patient-Reported Outcomes, Community-Engagement and Language (PRO-CEL) CoreP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · 1985 to 2025
$88.4M
SWOG NCORP Research BaseUG1CA189974 · OREGON HEALTH & SCIENCE UNIVERSITY · 2025 to 2025
$6.6M
Multicenter trial of decision support for breast cancer chemopreventionR01CA226060 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Katherine D Crew, Rita Kukafka · 2021 to 2023
$1.8M
National Clinical Trials Network Research at the University of WisconsinUG1CA233277 · UNIVERSITY OF WISCONSIN-MADISON · 2025 to 2025
$531k
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA226060NCI NIH HHS UG1 CA189974NCI NIH HHS UG1 CA233277
6 · The paper itself

Abstract

backgroundWomen with high-risk breast lesions, such as atypical hyperplasia (AH) or lobular carcinoma in situ (LCIS), have a 4- to tenfold increased risk of breast cancer compared to women with non-proliferative breast disease. Despite high-quality data supporting chemoprevention, uptake remains low. Interventions are needed to break down barriers.

methodsThe parent trial, MiCHOICE, is a cluster randomized controlled trial evaluating the effectiveness and implementation of patient and provider decision support tools to improve informed choice about chemoprevention among women with AH or LCIS. For this pre-implementation analysis, 25 providers participated in semi-structured interviews prior to accessing decision support tools. Interviews sought to understand attitudes/beliefs and barriers/facilitators to chemoprevention.

resultsInterviews with 25 providers (18 physicians and 7 advanced practice providers) were included. Providers were predominantly female (84%), white (72%), and non-Hispanic (88%). Nearly all providers (96%) had prescribed chemoprevention for eligible patients. Three themes emerged in qualitative analysis. The first theme describes providers' confidence in chemoprevention and the utility of decision support tools. The second theme elucidates barriers to chemoprevention, including time constraints, risk communication and perceptions of patients' fear of side effects and anxiety. The third theme is the need for early implementation of decision support tools.

conclusionsThis qualitative study suggests that providers were interested in the early inclusion of decision aids (DA) in their chemoprevention discussion workflow. The DAs may help overcome certain barriers which were elucidated in these interviews, including patient level concerns about side effects, clinic time constraints and difficulty communicating risk. A multi-faceted intervention with a DA as one active component may be needed.

trial registrationThis trial was registered with the NIH clinical trial registry, clinicaltrials.gov, NCT04496739.

Indexed as

Breast NeoplasmsChemopreventionQualitative ResearchAdultDecision Support TechniquesFemaleHumansInternetInterviews as TopicMaleMiddle Aged

Identifiers

PMID39334347
PMCPMC11430334

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.